Fourth Catalyst for a Cure Tackles Neurodegeneration

Made possible by visionary donors, our latest research initiative targets the shared roots of conditions that occur when neurons deteriorate and die.

In July 2022, a new team of brilliant investigators met for the first time to kick off the Melza M. and Frank Theodore Barr Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration. This bold research endeavor — the latest in the Foundation’s flagship research program — advances the quest for a future free from glaucoma by investigating what glaucoma has in common with Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).

Possibly the first biomedical research endeavor of its kind, the Neurodegeneration Initiative challenges conventional wisdom by applying the groundbreaking Catalyst for a Cure model of interdisciplinary teamwork across an entire family of diseases. By bringing together innovative investigators whose paths would not otherwise cross, the Catalyst model provides unique potential for outside-the-box scientific creativity — the kind of high-risk/high-reward research that rarely wins support from traditional funders.

With the Neurodegeneration Initiative under way, GRF is now funding two simultaneous Catalyst for a Cure consortia, each with the potential to change the lives of people with glaucoma. Ongoing since 2019, the Steven and Michele Kirsch Catalyst for a Cure Vision Restoration Initiative has made enormous strides that could soon result in the ability to protect, and even regenerate retinal ganglion cells — elements of the optic nerve that degenerate and die over time with glaucoma, causing blindness.

These and other complex conditions occur when nerve cells in the central nervous system — eye, brain, spinal cord — deteriorate and die, a process called neurodegeneration. “Neurodegeneration represents a promising but perplexing frontier in human health,” says Tom Brunner, President and CEO for Glaucoma Research Foundation. “Currently no therapies exist that can prevent or halt neurodegeneration or regrow healthy neurons and restore vision, memory, or other losses of function. We hope to contribute new insights that could lead to innovative treatments and cures for glaucoma as well as other neurodegenerative conditions.”

The Neurodegeneration Initiative was launched through a transformative $2.4 million gift to GRF from the Melza M. and Frank Theodore Barr Foundation. Philanthropist and former GRF board member Frank Theodore (Ted) Barr and his wife Melza have supported the Foundation for 40 years and were significant investors in the inaugural Catalyst for a Cure consortium. (Read more about the Barrs on page 6).

“The Neurodegeneration Initiative is one of the most exciting projects I’ve been involved with,” says Adriana Di Polo, PhD, Professor of Neuroscience at the University of Montreal, who is an award-winning neuroscientist, glaucoma pioneer, and scientific advisor for the new consortium. “It’s an unprecedented step forward — not just tackling glaucoma, but seeking cures for all neurodegenerative diseases.”
Meet the New Team of Investigators

The Melza M. and Frank Theodore Barr Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration will support creative collaboration by a team of four diversely talented young investigators. Trailblazers, pioneers, superstars in their chosen fields — all demonstrate creativity, a track record for innovative impact, a talent for collaboration, and a deep love of science.

Consortium members will start their work together by identifying promising avenues of investigation. The team will work together for an initial period of three years, guided by a group of expert scientific advisors.

Sandro Da Mesquita, PhD
Assistant Professor, Department of Neuroscience
Meningeal Lymphatics and Neurological Disorders Lab
Mayo Clinic
Dr. Da Mesquita’s unique expertise is in the field of central nervous system blood vessel biology, which has implications for Alzheimer’s and other neurodegenerative diseases.

Milica Margeta, MD, PhD
Physician and Surgeon
Massachusetts Eye and Ear
Assistant Professor of Ophthalmology
Harvard Medical School
Dr. Margeta is a glaucoma surgeon and a leader in the biology of microglia (immune cells of the brain and spinal cord) and in neuroinflammation.

Karthik Shekhar, PhD
Assistant Professor, Department of Chemical and Biomolecular Engineering
Faculty Scientist, Lawrence Berkeley Laboratory
Member, Helen Wills Neuroscience Institute
University of California Berkeley
A leader in computational biology, Dr. Shekhar has played a key role in collaborations that span neuroscience, immunology, single cell genomics, genetics, and machine learning, with a focus on visual systems.

Humsa Venkatesh, PhD
Assistant Professor, Program in Neuroscience
Brigham and Women’s Hospital
Harvard Medical School
Dr. Venkatesh’s discoveries have shaped the emerging field of cancer neuroscience, illuminating the nervous system’s role in disease progression.
The latest Catalyst for a Cure initiative builds on a paradigm-shifting discovery made by the first Catalyst team in 2006: More than a disease of the eye, glaucoma is a neurodegenerative condition, in the same family as Alzheimer’s disease.

**Q: What is neurodegeneration?**

**A:** Fundamental to many of these devastating illnesses, neurodegeneration occurs when nerve cells, the building blocks of the central nervous system, deteriorate and die. In glaucoma, neurodegeneration affects the retinal ganglion cells in the optic nerve, disconnecting the eye from the brain, and causing blindness over time. In Alzheimer’s, it affects nerve cells in the brain responsible for memory and cognition while in Parkinson’s, it affects nerve cells involved in movement and cognition. In many cases, these neurodegenerative diseases are thought to result from injury to nerve cell axons, the long, slender projections that conduct electrical impulses between nerve cells. Although multiple factors distinguish these diseases, understanding these common mechanisms that lead to axon injury and/or cell death is the key to the fourth Catalyst for a Cure initiative.

**Q: How will this initiative help people with glaucoma?**

**A:** Glaucoma and Alzheimer’s may appear to be unrelated. After all, people with Alzheimer’s do not necessarily develop glaucoma, nor vice versa. However, both diseases share a common cause: neurodegeneration. Investigating how these illnesses are alike and how they are different may illuminate new treatments, preventative measures, and cures for multiple conditions that trace their roots to neurodegeneration.

Aging, injury, inflammation, genetics — these factors and more may play a role in neurodegeneration and could indicate potential targets for unprecedented treatments and cures for glaucoma and Alzheimer’s. First, however, we must understand why and how neurons die, key questions we will explore through the Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration.
We are grateful for the generous and loyal support from all our donors. Following is a listing of recent contributions and pledges at the $1,000 level and above. Please note these are new contributions and pledges received between March 1, 2022 and June 30, 2022 and will not reflect a donor’s cumulative giving for the year.

### President’s Circle

**VISIONARIES ($200,000 - $999,999)**
- Melza M. and Frank Theodore Barr Foundation, Inc.
- Estate of John A. Goffette

**FOUNDERS ($50,000 to $99,999)**
- Alcon Laboratories, Inc.
- Rubin Obstgarten Family Foundation
- And one anonymous donor

**INNOVATORS ($25,000 to $49,999)**
- Eleanor McIntosh Trust
- Nanoscope Technologies LLC
- The Estate of Verona Shealy

**PACESETTERS ($10,000 to $24,999)**
- Aerie Pharmaceuticals, Inc.
- Wallace and Thomas M. Brunner
- Glaukos Corporation
- The Estate of Lorraine Mizuno
- Santen, Inc.
- Sonja W. Schluter, MD
- Sight Sciences, Inc.
- Vision International Eye Missions
- Charles and Catherine Wilmoth
- And one anonymous donor

### Catalyst Circle

**$5,000 to $9,999**
- Delta Gamma Foundation
- Elizabeth A. Lee and Stephen V. Lee and Families, in memory of Patricia M. Lee
- Kathryn Mayer
- MyEyes
- Pfund Family Foundation
- Saul J. Siemaska
- Sina Tamaddon
- Ruth D. Williams, MD and Stephen C. Gieser, MD, MPH
- And one anonymous donor

**$1,000 to $4,999**
- Abbvie Employee Engagement Fund
- Regina and Fred Amoroso
- The Jon and Isabelle Anderson Fund
- Carolyn Banchero
- Leslie Beam
- Nikki and David Brown Family Giving Fund
- Caterpillar Foundation
- Jeff Cebrynski
- Charities Aid Foundation of America
- Daniel O. Conkle
- Bertha Corbin
- Covalent Careers, Inc./Eyes on Glaucoma
- Drusilla D. Demmy and Henry Bowden
- Everlake Life Insurance Company
- Anthony R. Fisher, PhD
- Nancy and Robert Fluharty
- Paula and Michael Fritschen
- Nancy M. Graydon
- Fred Greenberg
- Eileen Guittano
- Tracy Hammond
- David Henderson
- Mitch C. Hill
- Donald and Judith Horowitz
- Judy Huang and John Lewis

---

**Each and Every Gift Moves Research Forward**

Your support will fund critical scientific investigations and bring us closer to a future free from glaucoma.

Please use the enclosed envelope or make a gift online at www.glaucoma.org/donate

For more information on how you can make a difference, contact: Nancy M. Graydon, Executive Director of Development and COO at 415-986-3162 ext. 231 or ngraydon@glaucoma.org
Meet Renaissance Innovators Ted and Melza Barr

The *Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration* is the inspiration of longtime GRF supporters Ted and Melza Barr. “We had been thinking about the challenge of neurodegeneration ever since the first *Catalyst for a Cure* identified it as a factor in glaucoma,” says Ted. “We thought it was time to better understand neurodegeneration in a fundamental way and develop solutions based on that knowledge.”

True renaissance innovators, the Barrs are a family of visionaries and philanthropists. Ted’s successful career in petroleum exploration and production motivated the family to support the communities that had contributed to their business success. In West Africa, the Barrs have funded infectious disease and public health programs, and education efforts. In the United States, they have advanced medical science, geological and environmental sciences, and the arts through the Melza M. and Frank Theodore Barr Foundation, founded in 2003.

The Barrs first became involved with glaucoma research after Ted experienced vision challenges while working in Indonesia in the early 1970s. With eye pressures that were especially high, Ted was referred to Dr. Robert Shaffer in San Francisco, where he connected with Dr. Shaffer and his partners Dr. Dunbar Hoskins and Dr. Jack Hetherington who would go on to found Glaucoma Research Foundation.

Further demonstrating their passion for quantum leaps, the Barrs have made a major gift to address some of biggest questions in planetary science. With their son, Terence, a CalTech alumnus, they have funded the Terence D. Barr Leadership Chair at the Caltech Center for Comparative Planetary Evolution. In a multidisciplinary model similar to GRF’s *Catalyst for a Cure*, the center unites scholars from astronomy, geology, and biology in exploring how planets form and evolve.

Following their curiosity, in 2021, the Barrs came to GRF with a bold proposition: Why not invest in research that could catalyze a quantum leap in our understanding of all neurodegenerative diseases, moving us closer to solutions for glaucoma, Alzheimer’s disease, and related conditions? With the Barrs’ generous support, GRF convened a virtual meeting-of-the-minds among top researchers to identify promising avenues for exploration. Encouraged by the results, the Barrs decided to invest further. “We have great confidence in the *Catalyst for a Cure* approach,” Ted says.
CATALYST FOR A CURE: A Synergistic Approach to Scientific Research

CATALYST FOR A CURE, GLAUCOMA RESEARCH FOUNDATION’S FLAGSHIP RESEARCH PROGRAM, TAKES A BOLD APPROACH TO DISCOVERY BY BREAKING DOWN TRADITIONAL RESEARCH SILOS AND BRINGING GREAT MINDS TOGETHER TOWARD A FUTURE FREE FROM GLAUCOMA.

Since 2002, GRF has introduced four Catalyst projects, each focused on a different aspect of glaucoma. For every initiative, scientific advisors select four top researchers from four leading institutions to form a consortium dedicated to eradicating glaucoma. Investigators start by partnering for three years. Based on progress, the GRF board may vote to extend a consortium’s funding for additional years.

The Catalyst discovery model is unique in the world of research, says John G. Flanagan, PhD, FCOptom, Dean of the Herbert Wertheim School of Optometry and Vision Science at UC Berkeley and Chair of the GRF Research Committee. “Scientists tend to work individually, or with close collaborators from a similar background, with an emphasis on competing for grant money,” Flanagan adds. In contrast, Catalyst investigators, working out of their own labs, pursue promising ideas together. “They are chosen to have different but complimentary skills and are tasked with answering research questions in partnership, report results as a team, and generate insights much more quickly than they could working alone,” he says.

The latest Catalyst consortium, the Neurodegenerative Initiative, breaks new ground in more ways than one. “First, top researchers rarely cross from one disease to another,” says Flanagan. “This initiative expands on the Catalyst model to identify commonalities among multiple, related diseases.” Second, the launch of the Neurodegeneration Initiative puts two Catalyst endeavors in motion at the same time. The two consortia are complementary rather than competitive, Flanagan points out. “Both teams have the same overall goal of preventing vision loss from glaucoma;” he explains. The Vision Restoration Initiative is concerned with restoring vision lost through neurodegeneration. Meanwhile, the Neurodegeneration Initiative will look at how neuronal death can be prevented, stopped, or reversed.

Dr. Flanagan believes the result will be a uniquely synergistic approach to discovery. “Adding a second, simultaneous Catalyst for a Cure brings four more labs with different capabilities to work on curing glaucoma,” he says. It also adds a second group of scientific advisors with different backgrounds to strengthen the effort. “We encourage collaboration between the two Catalyst teams and their advisors,” says Flanagan. “Our hope, with this latest initiative, is that we will gain new insights by comparing the mechanisms of neurodegeneration in glaucoma and Alzheimer’s diseases, with the aim of delivering both therapeutic and diagnostic advantages.”
GLEAMS
Glaucoma Research Foundation
251 Post Street, Suite 600
San Francisco, CA 94108

SAVE THE DATE!
FEBRUARY 2, 2023

gleamsofgala.org

Gleams is published three times a year by Glaucoma Research Foundation. 251 Post Street, Suite 600, San Francisco, CA 94108 Web: www.glaucoma.org Telephone: 415-986-3162 Toll Free: 800-826-6693 Email: gleams@glaucoma.org To unsubscribe, call 1-800-826-6693 or email “unsubscribe” to gleams@glaucoma.org.

©2022 by Glaucoma Research Foundation. All rights reserved. No parts of this publication may be reproduced without permission from the publisher. Gleams articles are intended to help readers understand glaucoma. Every effort is made to assure the accuracy of this information. This information is not a substitute for the advice and recommendations of a health professional. Always consult a health professional prior to any decision regarding your eyes or other health concerns. ISSN #1072-7906